In The News

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

December 28, 2019

TCT 2019: Low rate of MACE at 12 months with “world’s thinnest stent”

K Sivaprasad (Govt TD Medical College, Alappuzha, India) reported at the 2019 Transcatheter Cardiovascular Therapeutics (TCT) meeting (25–29 September, San Francisco, USA) yesterday that the Evermine 50 stent (Meril Life), which has a strut thickness of 50μm, is associated with a low rate of major adverse events (MACE) at 12 months.

In The News

Thin-Strut Bioresorbable Vascular Scaffold Shows Promise

December 27, 2019

Thin-Strut Bioresorbable Vascular Scaffold Shows Promise

The MeRes 100 thin-strut sirolimus-eluting bioresorbable scaffold, developed by Meril Life Sciences, demonstrated zero scaffold thrombosis and very low major adverse cardiac event rates for up to three years, according to two recent clinical trials.

In The News

At The Heart Of Life, At The Heart Of Precision - Get Pumped Up About Heart Health

December 26, 2019

At The Heart Of Life, At The Heart Of Precision - Get Pumped Up About Heart Health

Meril has become the first Indian company in the world to make the Transcatheter Aortic Valve Replacement (TAVR) therapy available for patients. The human heart has four valves that are synchronized to open and close according to the heart’s rhythm.

ABOUT

Founded in 2006, Meril is an India-based global medical device company that is dedicated to the innovation, design and development of novel, clinically relevant and state-of-the-art devices


LEARN MORE